Starling Oncology

STLN

----

Q2 FY2026 Earnings

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Starling Oncology(STLN) the Revenue is 161.28 M (+34.62%), Beat estimate;the EBIT is -4.616 M (+58.83%), Beat estimate;the EPS is -0.08 (+46.67%), Miss estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.16B34.62%

0.16B29.55%

+0.01B5.07%

EBITExceed expectations

-0.00B58.83%

-0.00B55.97%

+0.00B2.86%

EPSMiss expectations

-0.0846.67%

-0.06457.33%

-0.016010.66%

Upcoming earnings report - Q3 FY2026

Available dateNov 11, 2026

Estimate Revenue$168.69 M

Estimate EBIT-$3.589 M

Estimate EPS-$0.048

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly